The new CEO of Oxford Nanopore Technologies has begun work today as he takes over from founder Gordon Sanghera. Francis Van Parys (pictured) will now lead the FTSE 250 MedTech, which is eyeing profitability after also reporting its results for 2025. The DNA sequencing specialist reported revenues of £223.9 million, up 22.2% year-on-year, while adjusted … Continue reading New CEO as Oxford Nanopore eyes profitability amid legal action